Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

When we eat, our intestine produces two hormones called incretins: glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). When scientists discovered, in the 1990s ...

Tirzepatide (Mounjaro) also affects the glucose-dependent insulinotropic polypeptide (GIP) hormone, which controls metabolism and helps regulate energy balance. The first study into weight-loss ...

"We believe the data from this study will demonstrate that the combination of MC4R + GLP-1/GIP agonists may result in additive and synergistic effects on patient weight loss, and importantly ...

(Zepbound stimulates, rather than blocks, GIP, while both it and MariTide stimulate a second hormone called GLP-1 that’s become central to obesity treatment.) Helicore claims that, by blocking ...

HCR-188, a clinic-ready antibody, entering first-in-human clinical studies with top-line data anticipated in the second half of 2025 Building on existing validation of GIP pathway antagonism with ...